Pharmacokinetics of concentrated naloxone nasal spray for opioid overdose reversal: Phase I healthy volunteer study.

about

Pharmacokinetics of concentrated naloxone nasal spray for opioid overdose reversal: Phase I healthy volunteer study.

Item

http://www.wikidata.org/entity/Q44350979

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh-hant

name

Pharmacokinetics of concentrat ...... ase I healthy volunteer study.

@en

Pharmacokinetics of concentrat ...... ase I healthy volunteer study.

@nl

type

Item

label

Pharmacokinetics of concentrat ...... ase I healthy volunteer study.

@en

Pharmacokinetics of concentrat ...... ase I healthy volunteer study.

@nl

prefLabel

Pharmacokinetics of concentrat ...... ase I healthy volunteer study.

@en

Pharmacokinetics of concentrat ...... ase I healthy volunteer study.

@nl

P1476

Pharmacokinetics of concentrat ...... ase I healthy volunteer study.

@en

P2093

Björn Bosse

http://www.w3.org/2001/XMLSchema#string

Gill Mundin

http://www.w3.org/2001/XMLSchema#string

Helen Dooner

http://www.w3.org/2001/XMLSchema#string

Jo Woodward

http://www.w3.org/2001/XMLSchema#string

Kevin Smith

http://www.w3.org/2001/XMLSchema#string

Ulrike Lorch

http://www.w3.org/2001/XMLSchema#string

P2860

Preventing opiate overdose fatalities with take-home naloxone: pre-launch study of possible impact and acceptability.

Permeability issues in nasal drug delivery.

Assessment for deaths in out-of-hospital heroin overdose patients treated with naloxone who refuse transport.

The nasal approach to delivering treatment for brain diseases: an anatomic, physiologic, and delivery technology overview.

International patent applications for non-injectable naloxone for opioid overdose reversal: Exploratory search and retrieve analysis of the PatentScope database.

Pharmacokinetics of concentrated naloxone nasal spray over first 30 minutes post-dosing: analysis of suitability for opioid overdose reversal.

Estimating the burden of disease attributable to injecting drug use as a risk factor for HIV, hepatitis C, and hepatitis B: findings from the Global Burden of Disease Study 2013.

Intravenous vs subcutaneous naloxone for out-of-hospital management of presumed opioid overdose.

Naloxone--does over-antagonism matter? Evidence of iatrogenic harm after emergency treatment of heroin/opioid overdose.

Population pharmacokinetics of intravenous, intramuscular, and intranasal naloxone in human volunteers.

P304

484-493

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1111/ADD.14033

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

113

http://www.w3.org/2001/XMLSchema#string

P50

John Strang

Rebecca McDonald

P577

2017-11-16T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29143400

http://www.w3.org/2001/XMLSchema#string

P921

drug overdose

P932

5836974

http://www.w3.org/2001/XMLSchema#string